Clinical Trial Results:
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
Summary
|
|
EudraCT number |
2019-004496-39 |
Trial protocol |
NL |
Global end of trial date |
19 Jul 2024
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Jul 2025
|
First version publication date |
25 Jul 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
RGX-501-102
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04080050 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
REGENXBIO INC
|
||
Sponsor organisation address |
9804 Medical Center Dr, Rockville, United States, MD 20850
|
||
Public contact |
Medical Affairs , REGENXBIO INC, medinfo@regenxbio.com
|
||
Scientific contact |
Medical Affairs , REGENXBIO INC, , medinfo@regenxbio.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
19 Jul 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
19 Jul 2024
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
19 Jul 2024
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective is to evaluate the long-term safety of RGX-501.
|
||
Protection of trial subjects |
The study was conducted in accordance with the Declaration of Helsinki and with all applicable laws and regulations of the locales and countries where the study was conducted, and in compliance with Good Clinical Practice Guidelines.
|
||
Background therapy |
No study drug was administered in this study. All participants have previously received a single IV infusion of RGX-501 in a separate parent clinical study. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
04 Nov 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Netherlands: 2
|
||
Country: Number of subjects enrolled |
United States: 5
|
||
Country: Number of subjects enrolled |
Canada: 1
|
||
Worldwide total number of subjects |
8
|
||
EEA total number of subjects |
2
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
8
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||
Recruitment details |
Enrollment of each participant occurred the same day or after the participant completed the end of study visit or early termination visit from the previous parent study. Participants were followed in this study cumulatively for up to 5 years after RGX-501 administration or until RGX-501 was commercially available in the participant’s country. | ||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||
Screening details |
Screen failures were not applicable to this study. Every effort was made to recruit eligible participants in this study on the same day of their EOS visit or ETV from the parent study, or even after the participant has completed the parent study’s EOS visit or ETV. | ||||||||||||||||||||
Period 1
|
|||||||||||||||||||||
Period 1 title |
A Long-Term Follow-up Study (overall period)
|
||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||
Blinding implementation details |
Not applicable.
|
||||||||||||||||||||
Arms
|
|||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||
Arm title
|
Cohort 1 | ||||||||||||||||||||
Arm description |
The dose levels of RGX-501 vector administered in the parent study were 2.5 × 10^12 GC/kg. | ||||||||||||||||||||
Arm type |
Observational | ||||||||||||||||||||
Investigational medicinal product name |
RGX-501
|
||||||||||||||||||||
Investigational medicinal product code |
RGX-501
|
||||||||||||||||||||
Other name |
|||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||
Dosage and administration details |
This was a prospective, observational study to evaluate the long-term safety and efficacy after a single administration of RGX-501. RGX-501 was not administered in this study. Eligible participants were those who had previously enrolled in a parent clinical study (FHGT002) and received a single intravenous (IV) infusion of RGX-501.
|
||||||||||||||||||||
Arm title
|
Cohort 2 | ||||||||||||||||||||
Arm description |
The dose levels of RGX-501 vector administered in the parent study were 7.5 × 10^12 GC/kg. | ||||||||||||||||||||
Arm type |
Observational | ||||||||||||||||||||
Investigational medicinal product name |
RGX-501
|
||||||||||||||||||||
Investigational medicinal product code |
RGX-501
|
||||||||||||||||||||
Other name |
|||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||
Dosage and administration details |
This was a prospective, observational study to evaluate the long-term safety and efficacy after a single administration of RGX-501. RGX-501 was not administered in this study. Eligible participants were those who had previously enrolled in a parent clinical study (FHGT002) and received a single intravenous (IV) infusion of RGX-501.
|
||||||||||||||||||||
Arm title
|
Expansion Cohort 2 | ||||||||||||||||||||
Arm description |
The dose levels of RGX-501 vector administered in the parent study were 7.5 × 10^12 GC/kg. | ||||||||||||||||||||
Arm type |
Observational | ||||||||||||||||||||
Investigational medicinal product name |
RGX-501
|
||||||||||||||||||||
Investigational medicinal product code |
RGX-501
|
||||||||||||||||||||
Other name |
|||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||
Dosage and administration details |
This was a prospective, observational study to evaluate the long-term safety and efficacy after a single administration of RGX-501. RGX-501 was not administered in this study. Eligible participants were those who had previously enrolled in a parent clinical study (FHGT002) and received a single intravenous (IV) infusion of RGX-501.
|
||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Cohort 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The dose levels of RGX-501 vector administered in the parent study were 2.5 × 10^12 GC/kg. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Cohort 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The dose levels of RGX-501 vector administered in the parent study were 7.5 × 10^12 GC/kg. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Expansion Cohort 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The dose levels of RGX-501 vector administered in the parent study were 7.5 × 10^12 GC/kg. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Cohort 1
|
||
Reporting group description |
The dose levels of RGX-501 vector administered in the parent study were 2.5 × 10^12 GC/kg. | ||
Reporting group title |
Cohort 2
|
||
Reporting group description |
The dose levels of RGX-501 vector administered in the parent study were 7.5 × 10^12 GC/kg. | ||
Reporting group title |
Expansion Cohort 2
|
||
Reporting group description |
The dose levels of RGX-501 vector administered in the parent study were 7.5 × 10^12 GC/kg. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Incidence of AEs and SAEs over time [1] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The primary endpoints are the incidences of AEs and serious adverse events (SAEs) over time. TEAEs were defined as AEs that started or worsened during or after administration of RGX-501.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
5 years.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive summaries of safety measures are based on observed data. No imputation of missing data were implemented. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Absolute LDL-C levels by beta quantification | ||||||||||||||||
End point description |
Absolute LDL-C levels by beta quantification at Year 3 after RGX-501 administration.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
3 years
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Absolute total cholesterol over the study duration | ||||||||||||||||
End point description |
Absolute total cholesterol over the study duration, as available from medical records or collected as per standard of care (SOC).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
5 years.
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
LDL-C over the study duration | ||||||||||||||||
End point description |
LDL-C over the study duration, as available from medical records or collected as per standard of care (SOC).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
5 years
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Very low density lipoprotein cholesterol (VLDL-C) over the study duration [2] | ||||||||
End point description |
Very low density lipoprotein cholesterol (VLDL-C) over the study duration, as available from medical records or collected as per standard of care (SOC).
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
5 years.
|
||||||||
Notes [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Across all 3 cohorts, limited data are available regarding VLDL-C in the LTFU study for the enrolled population from baseline to the secondary efficacy endpoint. There is only data for a single participant at year 5 timepoint which limits the assessment of change from baseline to the secondary efficacy endpoint timepoints for VLDL-C. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
High density lipoprotein cholesterol (HDL-C) over the study duration | ||||||||||||||||
End point description |
High density lipoprotein cholesterol (HDL-C) over the study duration, as available from medical records or collected as per standard of care (SOC).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
5 years
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Calculated non-HDL-C over the study duration | ||||||||||||||||
End point description |
Calculated non-HDL-C over the study duration, as available from medical records or collected as per standard of care (SOC).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
5 years.
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Triglycerides (TG) over the study duration | ||||||||||||||||
End point description |
Triglycerides (TG) over the study duration, as available from medical records or collected as per standard of care (SOC).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
5 years.
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Lipoprotein a (Lp(a)) over the study duration [3] | ||||||||
End point description |
Lipoprotein a (Lp(a)) over the study duration as available from medical records or collected as per standard of care (SOC).
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
5 years.
|
||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Across all 3 cohorts, limited data were available regarding Lp(a) in the LTFU study for the enrolled population from baseline to secondary efficacy endpoint. Across all 3 cohorts, data were available for only 1 participant in cohort 2 for year 5 which limits the assessment of change from baseline for Lp(a). |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Usage of lipid-lowering therapies over time [4] | ||||||
End point description |
The number of participants who did not resume previously taken or did not initiate any new lipid-lowering treatment over time.
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
5 years
|
||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Across all 3 cohorts, only 1 (12.5%) participant did not resume previous lipid-lowering therapies and/or initiate new lipid-lowering treatment in the parent and LTFU studies for the enrolled population. |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||
End point title |
Summary of healthcare utilization | ||||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||||||
End point timeframe |
5 years.
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events are reported throughout the study for 5 years.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
23.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Cohort 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The dose levels of RGX-501 vector administered in the parent study were 2.5 × 10^12 GC/kg. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Cohort 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The dose levels of RGX-501 vector administered in the parent study were 7.5 × 10^12 GC/kg. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Expansion Cohort 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The dose levels of RGX-501 vector administered in the parent study were 7.5 × 10^12 GC/kg. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |